Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Cnri Los Angeles LLC

Neither a doctor nor a teaching hospital

Research payments

$1,783,026

144 payments

Through program year 2025, Cnri Los Angeles LLC is reported as receiving $1,783,026 in research payments, across 144 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $237,102 13
2024 Research $249,006 22
2023 Research $512,303 31
2021 Research $364,730 15
2020 Research $62,803 11
2019 Research $357,083 52

Breakdown

Who paid Research payments · program years 2019–2025
  1. Teva Pharmaceuticals USA, Inc. $704,323 53 payments
  2. Hoffmann-La Roche Limited $335,270 6 payments
  3. AbbVie, Inc. $247,132 10 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $117,399 2 payments
  5. Roche TCRC, Inc. $87,343 8 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $76,805 11 payments
  7. ITI, Inc. $66,901 5 payments
  8. Tolmar, Inc. $65,814 3 payments
  9. Otsuka Pharmaceutical Development & Commercialization, Inc. $48,470 3 payments
  10. Sunovion Pharmaceuticals Inc. $31,352 22 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients with Schizophrenia $704,323 53 payments
  2. Acute Schizophrenia Study $335,270 6 payments
  3. A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia $174,524 7 payments
  4. Proof of Concept in Schizophrenia $119,617 23 payments
  5. The Effect of 24Week Treatment With Basmisanil on Cognitive Impairment Associated With Schizophrenia $87,343 8 payments
  6. A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine 5, 10 and 20 mg in Adults With Major Depressive Disorder $72,180 8 payments
  7. Tol3010b $65,814 3 payments
  8. An Open-Label, MultiCenter Trial to Assess the Safety and Effectiveness of ITI-007 in Patients with Schizophrenia $60,447 4 payments
  9. A Phase Iiib Multi-Center, Open-Label, Mirror-Image, Study in Adult Subjects With Schizophrenia Treated Prospectively for 6-Months With Abilify Mycite $44,253 2 payments
  10. A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of00FFCVL-23100FF(Emraclidine) in Adult Participants With Schizophrenia $38,053 1 payment
What the money was spent on Research payments · program years 2019–2025
  1. Other $72,180 8 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record